Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



ADME predictions and molecular docking study of some compounds and drugs as potential inhibitors of COVID-19 main protease: A virtual study as comparison of computational results

Harun Uslu, Pelin Koparir, Kamuran Sarac, Arzu Karatepe.




Abstract

There is an urgent need for a drug to be used against COVID-19, which negatively affects human life worldwide and causes pandemic leading to the death of many people. Although some drugs are included in the treatment protocols of health institutions, there are currently no specific drugs against COVID-19 or are unknown, and effective treatment options remain very limited. Since designing a novel drug and testing its pharmacological properties may take long years, here we used a faster virtual study approach for some of our compounds with different chemical structures against COVID-19. Moreover, we included some drugs in this study and compared in silico results obtained. The activity potentials of these compounds were further evaluated through molecular docking studies with AutoDock4 and AutoDock Vina software. Among all the compounds studied, compounds 1a, 1b, and 1c demonstrate significant activity like other prodrugs, particularly against COVID-19. The most promising compound 1a has appropriate ADME prediction values and high binding affinity as a potential inhibitor of COVID-19 main protease.

Key words: COVID-19, molecular docking, ADME Predictions, favipiravir, remdesivir, hydroxychloroquine






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.